Share class: Aarti Pharmalabs Limited

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 90,626,008 47,519,340 ( 52.43 %) 0 52.43 %

Major shareholders: Aarti Pharmalabs Limited

NameEquities%Valuation
Life Insurance Corporation of India (Investment Portfolio)
5.276 %
4,782,452 5.276 % 38 M ₹
4.23 %
3,834,404 4.23 % 30 M ₹
3.535 %
3,204,310 3.535 % 25 M ₹
Anushakti Enterprise Private Ltd.
3.302 %
2,992,950 3.302 % 24 M ₹
Labdhi Business Trust
3.135 %
2,841,504 3.135 % 23 M ₹
3.106 %
2,815,612 3.106 % 22 M ₹
3.081 %
2,793,094 3.081 % 22 M ₹
2.805 %
2,542,750 2.805 % 20 M ₹
2.687 %
2,435,830 2.687 % 19 M ₹
1.573 %
1,425,900 1.573 % 11 M ₹
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Individuals29.59%
Other14.52%
Institutional5.88%
Governments0.34%
Unknown49.68%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals
29.59%
India
20.74%

Based on 1000 largest holdings

Logo Aarti Pharmalabs Limited
Aarti Pharmalabs Limited is engaged in the manufacturing of active pharmaceutical ingredients (APIs), advanced intermediates, and xanthine derivatives, based in India. The Company also offers comprehensive contract development and manufacturing organization (CDMO) and CMO services for drug substances and new chemical entities (NCE), including their key starting materials (KSM) and regulatory starting materials (RSM), serving various pharmaceutical companies worldwide with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of HPAPIs, corticosteroids, cytotoxic medicines, and oncology products. Its caffeine products include caffeine anhydrous, and caffeine anhydrous (granules). Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its products are exported to key regulated markets such as the United States (US), the European Union, and Japan.
Employees
2,162
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW